1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,480 | 3,520 | 27.06. | |
| 3,420 | 3,520 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy | 7 | Investing.com | ||
| 18.06. | Ladenburg Thalmann starts Elicio Therapeutics stock at buy | 4 | Investing.com | ||
| 17.06. | Elicio meldet vollständiges Ansprechen bei Bauchspeicheldrüsenkrebs-Patienten nach Folgetherapie | 11 | Investing.com Deutsch | ||
| 17.06. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer | 244 | GlobeNewswire (Europe) | 100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent... ► Artikel lesen | |
| 15.06. | Elicio Therapeutics Pancreatic Cancer Study Disappoints | 21 | Benzinga.com | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.06. | Elicio nosedives on phase 2 data for pancreatic cancer asset | 8 | Seeking Alpha | ||
| 15.06. | Rodman & Renshaw raises Elicio Therapeutics price target to $17.50 | 22 | Investing.com | ||
| 15.06. | Elicio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.06. | XFRA 9HA: WIEDERAUFNAHME/RESUMPTION | 218 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 15.06. | Elicio Therapeutics Says AMPLIFY-7P Study Did Not Meet Its Pre-specified Primary DFS Endpoint | 11 | RTTNews | ||
| 15.06. | Elicio Therapeutics Aktie bricht ein: Studie zu Bauchspeicheldrüsenkrebs verfehlt primären Endpunkt | 21 | Investing.com Deutsch | ||
| 15.06. | Elicio's pancreatic cancer trial misses primary endpoint | 3 | Investing.com | ||
| 15.06. | XFRA 9HA: AUSSETZUNG/SUSPENSION | 400 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILELICIO THERAP. DL-... ► Artikel lesen | |
| 15.06. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer | 536 | GlobeNewswire (Europe) | AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS") in the intent-to-treat population.Randomization balanced most prognostic factors between arms. However,... ► Artikel lesen | |
| 15.06. | Elicio repowers Bruges wind farm | 2 | reNews | ||
| 01.06. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology | 1 | GlobeNewswire (USA) | ||
| 11.05. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 11.05. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.04. | Elicio Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 2,090 | +1,95 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
23.06.2026 / 11:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| CLINUVEL | 5,904 | -1,73 % | Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,750 | +5,42 % | COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment | TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") announced the next steps in connection with changes to the Company's... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,820 | +0,78 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,931 | +1,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,000 | +0,25 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,892 | +1,53 % | RedHill Biopharma closes $6 million private placement | ||
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| MANNKIND | 3,577 | 0,00 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,360 Euro und damit -4,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.